Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1992-2-18
pubmed:abstractText
Pimobendan (UD-CG 115 BS), an inotropic agent and inhibitor of type III phosphodiesterase activity, is demethylated in vivo to form UD-CG 212 Cl, which is a more potent type III phosphodiesterase inhibitor. This study examined cyclic AMP (cAMP)-mediated actions of UD-CG 212 Cl. In guinea pig papillary muscles, UD-CG 212 Cl increased cAMP and stimulated Ca(++)-dependent slow action potentials (APs) in a dose-dependent manner. When compared to previous studies using pimobendan, UD-CG 212 Cl was approximately 100-fold more potent. UD-CG 212 Cl had no additional effects on slow APs in the presence of a maximal dose of isoproterenol (1 microM). Propranolol had little effect on UD-CG 212 Cl-induced slow APs. These results, along with previous studies, indicate that slow AP induction by UD-CG 212 Cl was cAMP-dependent, and the increase in cAMP levels was most likely due to phosphodiesterase inhibition and not beta receptor stimulation. Experiments with tetraethylammonium.Cl suggested that UD-CG 212 Cl probably did not induce slow APs by blocking K+ channels. In voltage-clamped ventricular myocytes UD-CG 212 Cl (100 microM) could stimulate Ca++ current (+21 +/- 5%) when basal cAMP levels were enhanced with a submaximal dose of isoproterenol (10(-9)-10(-8) M). Isoproterenol was not required to observe the stimulating effect of UD-CG 212 Cl on Ca++ current in intact, nondialyzed cells prepared using the nystatin-perforated patch method. Studies with the stereoisomers of UD-CG 212 Cl showed that the D-isomer was more potent than the L-isomer.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0022-3565
pubmed:author
pubmed:issnType
Print
pubmed:volume
260
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
58-63
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:1346167-Action Potentials, pubmed-meshheading:1346167-Adrenergic beta-Agonists, pubmed-meshheading:1346167-Adrenergic beta-Antagonists, pubmed-meshheading:1346167-Animals, pubmed-meshheading:1346167-Calcium, pubmed-meshheading:1346167-Cardiotonic Agents, pubmed-meshheading:1346167-Cells, Cultured, pubmed-meshheading:1346167-Cyclic AMP, pubmed-meshheading:1346167-Electrophysiology, pubmed-meshheading:1346167-Guinea Pigs, pubmed-meshheading:1346167-Heart, pubmed-meshheading:1346167-Heart Ventricles, pubmed-meshheading:1346167-Myocardial Contraction, pubmed-meshheading:1346167-Myocardium, pubmed-meshheading:1346167-Papillary Muscles, pubmed-meshheading:1346167-Phosphodiesterase Inhibitors, pubmed-meshheading:1346167-Pyridazines, pubmed-meshheading:1346167-Stereoisomerism, pubmed-meshheading:1346167-Tetraethylammonium, pubmed-meshheading:1346167-Tetraethylammonium Compounds, pubmed-meshheading:1346167-Ventricular Function
pubmed:year
1992
pubmed:articleTitle
Electrophysiological actions of the pimobendan metabolite, UD-CG 212 Cl, in guinea pig myocardium.
pubmed:affiliation
Department of Physiology and Biophysics, University of Illinois, Chicago.
pubmed:publicationType
Journal Article, In Vitro, Research Support, U.S. Gov't, P.H.S.